Baltimore, MD (PRWEB) February 10, 2009
Arrowhead's 2009 Personalized Medicine Conference is a full two day conference set to take place in Baltimore on April 23rd and 24th that will bring together leaders from industry, government and academia to discuss issues of central importance to the future of personalized medicine. Sessions will be held on a variety of topics integral to the development of personalized medicine, including, but not limited to:
- molecular diagnostics
Sessions will not only cover the various scientific and clinical developments in this space, but also a plethora of other issues that will need to be resolved in order to ensure success in this field, including:
- future regulatory models for personalized medicine
- social, ethical and legal concerns
- economic issues (insurance coverage, reimbursement, etc.)
Patrick Terry, the Co-Founder of Genomic Health and the Founder of the Personalized Medicine Coalition will share with attendees how innovative diagnostic companies are securing value-based rather than cost-based payment and will discuss how these innovators are building compelling clinical and economic evidence to support coverage and value-based payment from payers.
Attendees will also hear from Robert L. Becker, Jr, MD, Ph.D, the Chief Medical Officer of the FDA's Office of In Vitro Diagnostic Device Evaluation and Safety on the role of laboratory tests in personalized medicine and from Asif Dhar, MD, MBA, a Senior Fellow at the Deloitte Center for Health Solutions on the issue of ROI in targeted therapies. Specifically, Dr. Dhar will discuss the barriers facing developers of personalized medicine as well as the benefits of adopting personalized medicine.
Twenty five other speakers will be on hand to discuss the following issues:
- value creation in personalized medicine
- financial transparency in personalized medicine
- private insurance and Medicare coverage of personalized medicine
- the payors' perspective on personalized medicine
- the role of biomarkers and molecular diagnostics in the future of medicine
- how personalized medicine is faring in clinical trials
- perspectives on how clinicians will use personalized therapies in the future
- the role of health information technology and informatics in personalized medicine
- legal, regulatory and ethical concerns facing developers of personalized medicine
- personalized medicine business models and market analysis
Other key speakers:
Michael Amos, Ph.D., Scientific Advisor, Chemical Science & Technology Laboratory, National Institute of Standards & Technology Measurement, ex-officio member, Secretary's Advisory Committee on Genetics Health and Society (SACGHS), Department of Health and Human Services
Keith Batchelder, MD, Chief Executive Officer and Founder, Genomic Healthcare Strategies
Colin Brenan, Ph.D., Chief Technology Officer, VP Business Development, Co-Founder, BioTrove, Inc.
Teresa DeLuca, MD, Vice President Dept of Personalized Medicine, Medco
Professor Herbert A. Fritsche Jr., Ph.D., Professor & Chief of Clinical Chemistry, University of Texas M. D. Anderson Cancer Center
David Lester, Executive Vice President, Corporate Development, Gene Express Inc.
Thomas Metcalfe, Ph.D., Head, Personalized Healthcare Portfolio, F. Hoffmann-La Roche Ltd.
Bruce Quinn, MD, Ph.D., Senior Health Policy Specialist, Foley and Hoag
Rebekah Rasooly, Program Director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH)
Wayne Roe, Director, Celera Diagnostics, Director, In-Cube Ventures
Mollie Roth, Esq., Corporate Counsel, VP Business Development, Diaceutics
Surya Singh, M.D., Chief Medical Officer and Vice President of Clinical Development, Proventys, Inc.
Grail Sipes, Partner, Covington & Burling, Food and Drug Practice and Life Sciences Industry Group
For more information about this conference, please visit http://www.arrowheadpublishers.com or call 1-312-244-3703.